| Interferon pathway in SLE: one key to unlocking the mystery of the disease |
19 |
| Type I interferons in host defence and inflammatory diseases |
15 |
| Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus |
14 |
| Mouse models of lupus: what they tell us and what they don't |
13 |
| 10 most important contemporary challenges in the management of SLE |
13 |
| First use of cenerimod, a selective S1P(1) receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study |
12 |
| TNF-alpha and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus |
11 |
| Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE |
11 |
| Engaging African ancestry participants in SLE clinical trials |
10 |
| Obstetric antiphospholipid syndrome |
9 |
| Accelerated model of lupus autoimmunity and vasculopathy driven by toll-like receptor 7/9 imbalance |
9 |
| Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus |
9 |
| Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE |
7 |
| Remission and low disease activity in systemic lupus erythematosus: an achievable goal even with fewer steroids? Real-life data from a monocentric cohort |
7 |
| Changing paradigms in the treatment of systemic lupus erythematosus |
7 |
| Kynurenine pathway is altered in patients with SLE and associated with severe fatigue |
6 |
| QRISK3 improves detection of cardiovascular disease risk in patients with systemic lupus erythematosus |
6 |
| Patient-reported outcome measures for use in clinical trials of SLE: a review |
6 |
| Quantifying the burden of steroid-related damage in SLE in the Hopkins Lupus Cohort |
5 |
| Myocarditis in systemic lupus erythematosus diagnosed by F-18-fluorodeoxyglucose positron emission tomography |
5 |
| DNA methylation 101: what is important to know about DNA methylation and its role in SLE risk and disease heterogeneity |
5 |
| Alopecias in lupus erythematosus |
5 |
| Urine TWEAK level as a biomarker for early response to treatment in active lupus nephritis: a prospective multicentre study |
5 |
| Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus |
5 |
| Cell of origin in diffuse large B-cell lymphoma in systemic lupus erythematosus: molecular and clinical factors associated with survival |
4 |
| Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE |
4 |
| Assessing cognitive impairment in SLE: examining relationships between resting glucose metabolism and anti-NMDAR antibodies with navigational performance |
4 |
| Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers |
4 |
| Transition and transfer of the patient with paediatric-onset lupus: a practical approach for paediatric and adult rheumatology practices |
4 |
| Similar dysregulation of lupus-associated miRNAs in peripheral blood mononuclear cells and splenic lymphocytes in MRL/lpr mice |
4 |
| Association of lipoprotein subfractions and glycoprotein acetylation with coronary plaque burden in SLE |
3 |
| Lupus community panel proposals for optimising clinical trials: 2018 |
3 |
| Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE |
3 |
| Development of a systemic lupus erythematosus cardiovascular risk equation |
3 |
| Measuring plasma C4D to monitor immune complexes in lupus nephritis |
3 |
| Low hydroxychloroquine blood levels in patients who have had gastric bypass surgery |
3 |
| Hydroxychloroquine usage in US patients, their experiences of tolerability and adherence, and implications for treatment: survey results from 3127 patients with SLE conducted by the Lupus Foundation of America |
3 |
| SLE: reconciling heterogeneity |
3 |
| L-sepiapterin restores SLE serum-induced markers of endothelial function in endothelial cells |
2 |
| Cervus and cucumis peptides ameliorates bone erosion in experimental arthritis by inhibiting osteoclastogenesis |
2 |
| Global consensus building and prioritisation of fundamental lupus challenges: the ALPHA project |
2 |
| Risk of adverse events from different drugs for SLE: a systematic review and network meta-analysis |
2 |
| Iatrogenic antibody deficiency from B-cell targeted therapies in autoimmune rheumatic diseases |
2 |
| Plucked hair follicles from patients with chronic discoid lupus erythematosus show a disease-specific molecular signature |
2 |
| Associations between type I interferon and antiphospholipid antibody status differ between ancestral backgrounds |
2 |
| SLE clinical trials: impact of missing data on estimating treatment effects |
2 |
| Analysis of relationships between 25-hydroxyvitamin D, parathyroid hormone and cathelicidin with inflammation and cardiovascular risk in subjects with paediatric systemic lupus erythematosus: an Atherosclerosis Prevention in Paediatric Lupus Erythematosus (APPLE) study |
2 |
| Progression of subclinical and clinical cardiovascular disease in a UK SLE cohort: the role of classic and SLE-related factors |
2 |
| Tacrolimus in non-Asian patients with SLE: a real-life experience from three European centres |
2 |
| Increased alloreactive and autoreactive antihuman leucocyte antigen antibodies associated with systemic lupus erythematosus and rheumatoid arthritis |
2 |
